SANTA CLARA, Calif., July 18, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment cardiovascular disease, will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023. Company management will host…Read More
Related Posts
Multiple recent FDA approvals in pediatric rheumatology overcome delayed trials
SAN DIEGO -- The recent approvals of belimumab, golimumab, tofacitinib, secukinumab and ustekinumab in children with rheumatic diseases, all within the past 4 years, have changed the landscape in pediatric…
IMUNON Reports Interim ProgressionFree Survival and Overall Survival Data in Phase 12 OVATION 2 Study…
LAWRENCEVILLE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company focused on developing DNA-mediated immunotherapies and next-generation vaccines, announces interim progression-free survival (PFS) and…
New blood pressure related technique predicts health outcomes in patients Study
Boston [US], August 12 (ANI): Critically ill patients who are in circulatory shock, which happens when the heart is unable to pump enough blood and oxygen to the rest of…
